论文部分内容阅读
目的 Lung squamous cell carcinoma(LSQCC)is the second-largest histological subtype of lung cancer,which is the leading causeof cancer-related death in the world.Lobaplatin,one of the third-generation platinum compounds,has shown encouraginganticancer activity in a variety of tumors.The aim of this study was to determine the therapeutic efficacy of lobaplatin on p53-mutant lung squamous cancer cells Sk-MES-1.